Gilead Sciences, Inc. (BVL:GILDUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 720.84B +40.5% |
| Revenue (ttm) | 106.30B +6.5% |
| Net Income | -13.25B |
| EPS | -10.73 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 20.43 |
| Dividend | 11.00 (1.88%) |
| Ex-Dividend Date | Dec 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 170.33 |
| Day's Range | n/a |
| 52-Week Range | 110.25 - 170.33 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
Gilead announces results from PURPOSE 5 trial of lenacapavir
Gilead (GILD) Sciences announced results from the PURPOSE 5 trial showing significantly higher persistence-defined as consistent and continuous on-time use-among people starting twice-yearly injectabl...
Gilead announces results from Phase 3 IDEAL study of livdelzi
Gilead (GILD) Sciences announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi achieved the alkaline...
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®'s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants livin...
Gilead, Kite announce 23 presentations at ASH Annual Meeting
Gilead (GILD) Sciences and Kite, a Gilead Company announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology, ASH, Annual Meeting and Expo...
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th A...
3 Healthcare Stocks with ‘Strong Buy’ Analyst Ratings and ‘Perfect 10’ Smart Scores
Eli Lilly ($LLY), UnitedHealth ($UNH), and Gilead Sciences ($GILD) are three healthcare stocks with Strong Buy analyst ratings. All three stocks also have a Perfect 10 Smart Score on TipRanks.
Gilead to present clinical data, real-world evidence at HIV Glasgow
Gilead (GILD) Sciences announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection, taking place from November 8-11. Results from more than 50 studies, includin...
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection (HIV Glasgo...
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare ...
Gilead price target raised to $200 from $177 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Gilead (GILD) to $200 from $177 and keeps an Outperform rating on the shares. The firm believes the price target…
Gilead price target raised to $183 from $163 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $183 from $163 and keeps an Overweight rating on the shares.
Gilead price target raised to $190 from $170 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Gilead (GILD) to $190 from $170 and keeps an Overweight rating on the shares.
Gilead price target raised to $181 from $158 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Gilead (GILD) to $181 from $158 and keeps a Buy rating on the shares. The company delivered a beat on…
Gilead price target raised to $175 from $160 at TD Cowen
TD Cowen analyst Tyler Van Buren raised the firm’s price target on Gilead (GILD) to $175 from $160 and keeps a Buy rating on the shares. The firm said Q3…
Gilead price target raised to $195 from $175 at UBS
UBS raised the firm’s price target on Gilead (GILD) to $195 from $175 and keeps a Buy rating on the shares. Gilead posted a strong Q3 beat and raise driven…
Gilead price target raised to $175 from $155 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Gilead (GILD) to $175 from $155 and keeps an Overweight rating on the shares. Gilead delivered its largest revenue beat since the…
Gilead price target raised to $200 from $170 at Needham
Needham raised the firm’s price target on Gilead (GILD) to $200 from $170 and keeps a Buy rating on the shares. The company’s topline Q3 beat was again highlighted by…
Gilead price target raised to $188 from $165 at Citi
Citi raised the firm’s price target on Gilead (GILD) to $188 from $165 and keeps a Buy rating on the shares. The company’s Q3 report reinforced confidence in the durability…
Gilead price target raised to $190 from $165 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Gilead (GILD) to $190 from $165 and keeps an Overweight rating on the shares. The firm thinks Gilead’s Q3…
Gilead Sciences Earnings Call Transcript: Q3 2026
Base business sales rose 16% YoY to $8.2B, the strongest growth in more than a decade, prompting higher FY2026 guidance. Strong HIV, TRODELVY and Livdelzi results were tempered by cell therapy competition and a projected ~$1.5B 2028 BIKTARVY pricing impact.
Gilead Sciences Earnings release: Q3 2026
Gilead Sciences released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Gilead Sciences Slides: Q3 2026
Gilead Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Gilead Sciences Prepared remarks: Q3 2026
Gilead Sciences filed a regulatory document on October 29, 2026 disclosing important business information.
Gilead Sciences Quarterly report: Q3 2026
Gilead Sciences has published its Q3 2026 quarterly earnings report on October 29, 2026.
Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
The biopharmaceutical company said it now expects full-year product sales of $31 billion to $31.3 billion, up from $30.1 billion to $30.4 billion.